These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19739129)

  • 1. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.
    Wang Y; Gupta S; Hua V; Ramos-Garcia R; Shevrin D; Jovanovic BD; Nelson JB; Wang Z
    Prostate; 2010 Feb; 70(2):147-54. PubMed ID: 19739129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride.
    Umekita Y; Hiipakka RA; Kokontis JM; Liao S
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
    Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
    J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
    Masoodi KZ; Ramos Garcia R; Pascal LE; Wang Y; Ma HM; O'Malley K; Eisermann K; Shevrin DH; Nguyen HM; Vessella RL; Nelson JB; Parikh RA; Wang Z
    Endocrinology; 2013 Jul; 154(7):2296-307. PubMed ID: 23671262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model.
    Eggener SE; Stern JA; Jain PM; Oram S; Ai J; Cai X; Roehl KA; Wang Z
    Prostate; 2006 Apr; 66(5):495-502. PubMed ID: 16372330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.
    Garcia RR; Masoodi KZ; Pascal LE; Nelson JB; Wang Z
    Am J Clin Exp Urol; 2014; 2(1):82-91. PubMed ID: 25374909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
    Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
    PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells.
    Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J
    J Androl; 2003; 24(5):681-7. PubMed ID: 12954658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.
    Parikh RA; Pascal LE; Davies BJ; Wang Z
    Asian J Androl; 2014; 16(4):505-10. PubMed ID: 24759577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW
    Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of testosterone during androgene deprivation therapy].
    Vallat A; Pillot P; Lebâcle C; Irani J
    Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate.
    Yamashita A; Hayashi N; Sugimura Y; Cunha GR; Kawamura J
    Prostate; 1996 Jul; 29(1):1-14. PubMed ID: 8685049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genes expressed in the rat prostate that are modulated differently by castration and Finasteride treatment.
    Avila DM; Fuqua SA; George FW; McPhaul MJ
    J Endocrinol; 1998 Dec; 159(3):403-11. PubMed ID: 9834458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.